AU2020102504A4 - Prostate cancer ontology and construction method thereof - Google Patents
Prostate cancer ontology and construction method thereof Download PDFInfo
- Publication number
- AU2020102504A4 AU2020102504A4 AU2020102504A AU2020102504A AU2020102504A4 AU 2020102504 A4 AU2020102504 A4 AU 2020102504A4 AU 2020102504 A AU2020102504 A AU 2020102504A AU 2020102504 A AU2020102504 A AU 2020102504A AU 2020102504 A4 AU2020102504 A4 AU 2020102504A4
- Authority
- AU
- Australia
- Prior art keywords
- prostate cancer
- pca
- ontology
- prostate
- concepts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 145
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 139
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 26
- 208000024891 symptom Diseases 0.000 claims abstract description 17
- 238000003745 diagnosis Methods 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 7
- 238000001794 hormone therapy Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 230000001973 epigenetic effect Effects 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 238000003759 clinical diagnosis Methods 0.000 claims description 5
- 238000000315 cryotherapy Methods 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 108700012941 GNRH1 Proteins 0.000 claims description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 3
- 238000002725 brachytherapy Methods 0.000 claims description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 238000002710 external beam radiation therapy Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 230000027939 micturition Effects 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000013188 needle biopsy Methods 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
- 238000011472 radical prostatectomy Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract description 34
- 102100038358 Prostate-specific antigen Human genes 0.000 abstract description 34
- 238000005259 measurement Methods 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 7
- 206010036018 Pollakiuria Diseases 0.000 abstract description 6
- 208000022934 urinary frequency Diseases 0.000 abstract description 6
- 230000036318 urination frequency Effects 0.000 abstract description 6
- 230000002485 urinary effect Effects 0.000 abstract description 3
- 206010006002 Bone pain Diseases 0.000 abstract description 2
- 238000012351 Integrated analysis Methods 0.000 abstract description 2
- 206010027566 Micturition urgency Diseases 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000012830 cancer therapeutic Substances 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 229940011871 estrogen Drugs 0.000 abstract description 2
- 239000000262 estrogen Substances 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 239000002207 metabolite Substances 0.000 abstract description 2
- 206010029446 nocturia Diseases 0.000 abstract description 2
- 208000023958 prostate neoplasm Diseases 0.000 abstract description 2
- 208000026455 prostate symptom Diseases 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 210000001635 urinary tract Anatomy 0.000 abstract description 2
- 238000011160 research Methods 0.000 description 13
- 239000003098 androgen Substances 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002214 protein ontology Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 101100042848 Rattus norvegicus Smok gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 102000048851 human CD44 Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/30—Information retrieval; Database structures therefor; File system structures therefor of unstructured textual data
- G06F16/36—Creation of semantic tools, e.g. ontology or thesauri
- G06F16/367—Ontology
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/30—Information retrieval; Database structures therefor; File system structures therefor of unstructured textual data
- G06F16/31—Indexing; Data structures therefor; Storage structures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Data Mining & Analysis (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Databases & Information Systems (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Evolutionary Biology (AREA)
- Primary Health Care (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Artificial Intelligence (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Computational Linguistics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Machine Translation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010729262.7 | 2020-07-27 | ||
| CN202010729262.7A CN111916146B (zh) | 2020-07-27 | 2020-07-27 | 前列腺癌本体及其构建方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020102504A4 true AU2020102504A4 (en) | 2020-11-19 |
Family
ID=73249795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020102504A Ceased AU2020102504A4 (en) | 2020-07-27 | 2020-09-29 | Prostate cancer ontology and construction method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111916146B (zh) |
| AU (1) | AU2020102504A4 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112466463B (zh) * | 2020-12-10 | 2023-08-18 | 求臻医学科技(浙江)有限公司 | 基于肿瘤精准诊疗知识图谱的智能解答系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101827125B (zh) * | 2010-03-31 | 2013-04-10 | 吉林大学 | 语义Web服务本体及其应用 |
| EP2576835A4 (en) * | 2010-06-01 | 2013-10-30 | Univ Laval | PROGNOSTIC MARKERS OF A PROSTATE CANCER RECHUTE |
| US20130096944A1 (en) * | 2011-10-13 | 2013-04-18 | The Board of Trustees of the Leland Stanford, Junior, University | Method and System for Ontology Based Analytics |
| CN105808706B (zh) * | 2016-03-06 | 2019-01-29 | 中国人民解放军国防科学技术大学 | 基于应用本体的空间目标识别方法 |
| CN106367527A (zh) * | 2016-11-17 | 2017-02-01 | 苏州大学附属第二医院 | 直肠癌放化疗疗效相关靶基因的鉴定 |
| CN108830027A (zh) * | 2017-05-03 | 2018-11-16 | 天津中医药大学 | 一种中医网络证候学分析平台及构建方法和应用 |
| CN107437004B (zh) * | 2017-08-07 | 2020-06-19 | 深圳华大基因研究院 | 一种用于肿瘤个体化基因检测智能解读的系统 |
| US11488713B2 (en) * | 2017-08-15 | 2022-11-01 | Computer Technology Associates, Inc. | Disease specific ontology-guided rule engine and machine learning for enhanced critical care decision support |
| CN108206057A (zh) * | 2018-03-14 | 2018-06-26 | 苏州大学 | 一种前列腺癌诊疗数据平台 |
| KR102193272B1 (ko) * | 2018-09-11 | 2020-12-22 | 인하대학교 산학협력단 | 당뇨병 치료를 위한 시맨틱스 지능형 임상결정 지원 시스템 |
| CN109271530A (zh) * | 2018-10-17 | 2019-01-25 | 长沙瀚云信息科技有限公司 | 一种疾病知识图谱构建方法和平台系统、设备、存储介质 |
| CN111157001B (zh) * | 2019-12-20 | 2022-11-18 | 南京师范大学 | 一种面向医院室内导航的本体构建方法 |
-
2020
- 2020-07-27 CN CN202010729262.7A patent/CN111916146B/zh active Active
- 2020-09-29 AU AU2020102504A patent/AU2020102504A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN111916146A (zh) | 2020-11-10 |
| CN111916146B (zh) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Systematic evaluation of research progress on natural language processing in medicine over the past 20 years: bibliometric study on PubMed | |
| Wang et al. | Clinical information extraction applications: a literature review | |
| US20200243175A1 (en) | Health information system for searching, analyzing and annotating patient data | |
| Yang et al. | Mining health social media with sentiment analysis | |
| Savova et al. | DeepPhe: a natural language processing system for extracting cancer phenotypes from clinical records | |
| Lim et al. | An unsupervised machine learning model for discovering latent infectious diseases using social media data | |
| MacLean et al. | Identifying medical terms in patient-authored text: a crowdsourcing-based approach | |
| Chang et al. | The use of SNOMED CT, 2013-2020: a literature review | |
| Ho et al. | Data-driven approach to detect and predict adverse drug reactions | |
| Dingerdissen et al. | OncoMX: a knowledgebase for exploring cancer biomarkers in the context of related cancer and healthy data | |
| Zeng et al. | Identifying breast cancer distant recurrences from electronic health records using machine learning | |
| Luo et al. | A human–computer collaborative approach to identifying common data elements in clinical trial eligibility criteria | |
| Hanauer et al. | Applying MetaMap to Medline for identifying novel associations in a large clinical dataset: a feasibility analysis | |
| Boland et al. | Feasibility of feature-based indexing, clustering, and search of clinical trials | |
| Xiu et al. | Construction of a digestive system tumor knowledge graph based on chinese electronic medical records: development and usability study | |
| Báez et al. | Automatic extraction of nested entities in clinical referrals in Spanish | |
| He et al. | A method for analyzing commonalities in clinical trial target populations | |
| Ouyang et al. | Evolutionary overview of consumer health informatics: bibliometric study on the Web of Science from 1999 to 2019 | |
| AU2020102504A4 (en) | Prostate cancer ontology and construction method thereof | |
| Lu et al. | Exploring health-related topics in online health community using cluster analysis | |
| Liu et al. | Ontology-based categorization of clinical studies by their conditions | |
| Rahaman | Discovering new trends & connections: current applications of biomedical text mining | |
| Přečková et al. | Measuring diversity in medical reports based on categorized attributes and international classification systems | |
| Neustein et al. | Application of text mining to biomedical knowledge extraction: analyzing clinical narratives and medical literature | |
| Huang et al. | Development of the Lymphoma Enterprise Architecture Database: A caBIG™ Silver Level Compliant System |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |